NBTX logo

NANOBIOTIX SA - ADR

NBTXNASDAQ
🏆 #2141 by market capUS Equity
$31.86▼ $0.81 (−2.54%)
Live
🔔
Track NBTX
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 2.5%
7d▼ 10.1%
14d▼ 10.0%
30d▼ 22.8%
ytd▲ 37.3%
1y▲ 76.5%
🏦Market Cap
$1.61B
Small Cap
📈Revenue Growth (YoY)
+512.3%
High Growth
📊Gross Margin
45.2%
Healthy
💵FCF Margin
-587.6%
Thin
⚖️P/S Ratio
213.1x
Expensive
Otter Score
84
Good

Trading Snapshot

Day Range
$31.75 – $32.48
52-Week Range
$14.78 – $57.14
Volume
$2.25B
Avg Volume
$2.90B
Shares Outstanding
50.6M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$30M
Last Q Revenue
$4M
P/E Ratio
-25.3
P/S Ratio
213.1x
EPS (TTM)
$-1.08
Dividend Yield
0.00%
Dilution (1yr)
+1.2%

Why Investors Own NBTX

  • ✓High-growth profile — revenue up +23.2% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 50% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NBTX logo

NANOBIOTIX SA - ADR

NBTX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$30M▼ −512.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −84.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$34M▲ +66.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.8M▲ +1.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$43M▼ −$41M YoY
StockOtter · stockotter.space

About NANOBIOTIX SA - ADR

Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles. This treatment is currently undergoing development for its potential application in a broad spectrum of cancers, including soft tissue sarcoma, various head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has established a strategic collaboration with LianBio for the development and commercialization of NBTXR3 within key Asian markets, specifically Greater China, South Korea, Singapore, and Thailand. Founded in 2003, the company's main operations are situated in Paris, France.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$37.11
▲ +16.5% Upside
High Target$41.38
Low Target$30.42
Based on 11 analysts

Latest News & Updates

🚀
Barron’s·2h ago

NANOBIOTIX SA - ADR tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift NBTX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

NANOBIOTIX SA - ADR announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.